Translational Drug Disposition: Enabling the Move Away from One Dose for All

Impact: Cultural impacts, Economic impacts, Health impacts, Political impacts, Technological impacts


The Centre for Applied Pharmacokinetic Research (CAPKR) has been conducting world leading resaerch in translational drug disposition, as demonstrable by very high citations from peers. However, more importantly, the research has played a significant role, as indicated by testimonials from top regulatory scientists and leadership of pharmaceutical industry, in shifting he paradigm of the development away from "one dose for all" strategies. This particularly serves sub-populations (such as neonates and paediatrics, renal failure patients, obese patients undergoing bariatric surgery, pregnant women) who are not served well with current practices dose finding studies (with man excusion criteria during so called Phase II studies)
Our path to imapact involved close collaborations with FDA and leading pharmaceutiocal companies in areas of (i) optimising in vitro studies of drug disposition, (ii) translation of human proteomics for extrapolating the in vitro data, (iii) creating advanced mechanistic models for human drug disposition, and (iv) reverse translation from clinical observations by applying mechanistic models as part of data analysis

Category of impact

  • Cultural impacts
  • Economic impacts
  • Health impacts
  • Political impacts
  • Technological impacts
1 Jan 2007 - 21 Jun 2019